Hepatic sirtuin 1 is dispensable for fibrate-induced peroxisome proliferator-activated receptor-α function in vivo

American Journal of Physiology - Endocrinology and Metabolism

Volumn 306, Issue 7, 2014, Pages

  Bonzo, Jessica A ^a   Brocker, Chad ^a   Jiang, Changtao ^a   Wang, Rui Hong ^b   Deng, Chu Xia ^b   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Fibrates; Peroxisome proliferator activated receptor ; Sirtuin 1

Indexed keywords

FIBRIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SIRTUIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY MASS; CONTROLLED STUDY; DIET RESTRICTION; GENE EXPRESSION; IN VIVO STUDY; LIPID DIET; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

FIBRATES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Α; SIRTUIN 1;

ANIMALS; CELL PROLIFERATION; FIBRIC ACIDS; GENE EXPRESSION; HEPATOCYTES; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PPAR ALPHA; SIRTUIN 1; UP-REGULATION;

EID: 84900555874     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00175.2013     Document Type: Article

References (38)

1. Biddinger SB, Almind K, Miyazaki M, Kokkotou E, Ntambi JM, Kahn CR. Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome. Diabetes 54: 1314-1323, 2005.
2. Bumpus NN, Johnson EF. 5-Aminoimidazole-4-carboxyamide-ribonucleoside (AICAR)-stimulated hepatic expression of Cyp4a10, Cyp4a14, Cyp4a31, and Other peroxisome proliferator-activated receptor β-responsive mouse genes Is AICAR 5′-monophosphate-dependent and AMPactivated protein kinase-independent. J Pharmacol Exp Ther 339: 886-895, 2011.
3. Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P, Auwerx J. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458: 1056-1060, 2009.
4. Caton PW, Holness MJ, Bishop-Bailey D, Sugden MC. PPARalpha-LXR as a novel metabolostatic signalling axis in skeletal muscle that acts to optimize substrate selection in response to nutrient status. Biochem J 437: 521-530, 2011.
5. Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123: 437-448, 2005.
6. Duhaney TA, Cui L, Rude MK, Lebrasseur NK, Ngoy S, De Silva DS, Siwik DA, Liao R, Sam F. Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload. Hypertension 49: 1084-1094, 2007.
7. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferatoractivated receptors alpha and delta. Proc Natl Acad Sci USA 94: 4312-4317, 1997.
8. Guarente L. Sirtuins, aging, and metabolism. Cold Spring Harb Symp Quant Biol 76: 81-90, 2011.
9. Guzmán M, Lo Verme J, Fu J, Oveisi F, Blázquez C, Piomelli D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem 279: 27849-27854, 2004.
10. Hayashida S, Arimoto A, Kuramoto Y, Kozako T, Honda S, Shimeno H, Soeda S. Fasting promotes the expression of SIRT1, an NAD+-dependent protein deacetylase, via activation of PPARalpha in mice. Mol Cell Biochem 339: 285-292, 2010.
11. Houtkooper RH, Cantó C, Wanders RJ, Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 31: 194-223, 2010.
12. Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 13: 225-238, 2012.
13. Jolley CD, Dietschy JM, Turley SD. Genetic differences in cholesterol absorption in 129/Sv and C57BL/6 mice: effect on cholesterol responsiveness. Am J Physiol Gastrointest Liver Physiol 276: G1117-G1124, 1999.
14. Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 13: 2570-2580, 1999.
15. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103: 1489-1498, 1999.
16. Lalloyer F, Staels B. Fibrates, glitazones, and peroxisome proliferatoractivated receptors. Arterioscler Thromb Vasc Biol 30: 894-899, 2010.
17. Lee JY, Hashizaki H, Goto T, Sakamoto T, Takahashi N, Kawada T. Activation of peroxisome proliferator-activated receptor-alpha enhances fatty acid oxidation in human adipocytes. Biochem Biophys Res Commun 407: 818-822, 2011.
18. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15: 3012-3022, 1995.
19. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest 116: 571-580, 2006.
20. Liang F, Kume S, Koya D. SIRT1 and insulin resistance. Nat Rev Endocrinol 5: 367-373, 2009.
21. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137-148, 2001.
22. Patsouris D, Reddy JK, Muller M, Kersten S. Peroxisome proliferatoractivated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 147: 1508-1516, 2006.
23. Peters JM, Cattley RC, Gonzalez FJ. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 18: 2029-2033, 1997.
24. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
25. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschöp MH. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci USA 105: 9793-9798, 2008.
26. Ponugoti B, Kim DH, Xiao Z, Smith Z, Miao J, Zang M, Wu SY, Chiang CM, Veenstra TD, Kemper JK. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem 285: 33959-33970, 2010.
27. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 9: 327-338, 2009.
28. Purushotham A, Xu Q, Lu J, Foley JF, Yan X, Kim DH, Kemper JK, Li X. Hepatic deletion of SIRT1 decreases hepatocyte nuclear factor 1α/farnesoid X receptor signaling and induces formation of cholesterol gallstones in mice. Mol Cell Biol 32: 1226-1236, 2012.
29. Selim E, Frkanec JT, Cunard R. Fibrates upregulate TRB3 in lymphocytes independent of PPAR alpha by augmenting CCAAT/enhancerbinding protein beta (C/EBP beta) expression. Mol Immunol 44: 1218-1229, 2007.
30. Shah YM, Morimura K, Yang Q, Tanabe T, Takagi M, Gonzalez FJ. Peroxisome proliferator-activated receptor alpha regulates a microRNAmediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol 27: 4238-4247, 2007.
31. Shin M, Ohnishi M, Iguchi S, Sano K, Umezawa C. Peroxisomeproliferator regulates key enzymes of the tryptophan-NAD+ pathway. Toxicol Appl Pharmacol 158: 71-80, 1999.
32. Vaziri H, Dessain SK, Eaton EN, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA. hSIR2(SIRT1) functions as an NAD-Dependent p53 Deacetylase. Cell 107: 149-159, 2001.
33. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C, Kim S, Xu X, Zheng Y, Chilton B, Jia R, Zheng ZM, Appella E, Wang XW, Ried T, Deng CX. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14: 312-323, 2008.
34. Wang RH, Zheng Y, Kim HS, Xu X, Cao L, Lahusen T, Lee MH, Xiao C, Vassilopoulos A, Chen W, Gardner K, Man YG, Hung MC, Finkel T, Deng CX. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell 32: 11-20, 2008.
35. Wang RH, Li C, Deng CX. Liver steatosis and increased ChREBP expression in mice carrying a liver specific SIRT1 null mutation under a normal feeding condition. Int J Biol Sci 6: 682-690, 2010.
36. Xu F, Gao Z, Zhang J, Rivera CA, Yin J, Weng J, Ye J. Lack of SIRT1 (Mammalian Sirtuin 1) activity leads to liver steatosis in the SIRT1+/-mice: a role of lipid mobilization and inflammation. Endocrinology 151: 2504-2514, 2010.
37. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96: 7324-7329, 1999.
38. Yamashita M. PPARalpha/gamma-Independent Effects of PPARalpha/ gamma Ligands on Cysteinyl Leukotriene Production in Mast Cells. PPAR Res 2008: 293538, 2008.